Affiliations: [a] The Neuro (Montreal Neurological Institute-Hospital), Montréal, QC, Canada
Department of Neurology and neurosurgery, McGill University, Montréal, QC, Canada
| [c] Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA
Department of Human Genetics, McGill University, Montréal, QC, Canada
| [e] Cancer and Population Studies group, Population Health Department, QIMR Berghofer Medical Research Institute, Locked Bag 2000, Royal Brisbane Hospital, Queensland, Australia
Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, UK
Correspondence to: Ziv Gan-Or, MD, PhD, Department of Neurology and Neurosurgery, McGill University, 1033 Pine Avenue, West, Ludmer Pavilion, room 312, Montreal, QC, H3A 1A1, Canada. Tel.: +1 514 398 5845; Fax: +1 514 398 8248; E-mail: [email protected].
Abstract: Background:Epidemiological data suggest that cancer patients have a reduced risk of subsequent Parkinson’s disease (PD) development, but the prevalence of PD in melanoma patients is often reported to be increased. Causal relationships between cancers and PD have not been fully explored. Objective:To study causal relationship between different cancers and PD. Methods:We used GWAS summary statistics of 15 different types of cancers and two-sample Mendelian randomization to study the causal relationship with PD. Results:There was no evidence to support a causal relationship between the studied cancers and PD. We also performed reverse analyses between PD and cancers with available full summary statistics (melanoma, breast, prostate, endometrial and keratinocyte cancers) and did not find evidence of causal relationship. Conclusion:We found no evidence to support a causal relationship between cancers and PD and the previously reported associations could be a result of genetic pleiotropy, shared biology or biases.